Q-omics provides the consensus-scored CRYGD profile across patient tissues and cancer cell-line models. CRYGD expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CRYGD is differentially expressed in 5, with the highest sampling consensus in BLCA. Additionally, CRYGD RNA expression shows 8,279 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, BLCA, and TGCT as cancer lineages where CRYGD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRYGD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRYGD survival associations across molecular data types. CRYGD RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRYGD RNA expression–survival associations across cancer types. High CRYGD expression shows unfavorable associations in MESO, KIRC, BLCA, DLBC and UCS, but favorable associations in HNSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CRYGD RNA expression.
This table summarizes CRYGD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5, while mass-spec protein shows differences in 2. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CRYGD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRYGD shows lower tumor expression in BLCA, BRCA, UCEC, PRAD and COAD. The BLCA box plot shows higher CRYGD RNA expression in normal versus tumor tissue (log2 FC = −0.312, t-test p = .003).
This table shows molecular features associated with CRYGD in patient tissues and cancer cell lines. In patient samples, CRYGD shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CRYGD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SKIN.
